Background & AimsDaily step count measures cardiorespiratory fitness and has been associated with clinical outcomes. However, its utility in patients with cirrhosis remains largely unexplored. We aimed to investigate the association between step count, frailty metrics, and clinical outcomes in cirrhosis.MethodsAll participants underwent frailty evaluation with the liver frailty index, 6-minute walk test, and gait …
Category: Hepatology
Risk of fractures and subsequent mortality in alcohol-related cirrhosis: A nationwide population-based cohort study
Background and aimsAlcohol-related cirrhosis is linked to increased risk of fractures, but this has seldom been quantified nationally or compared against non-cirrhotic controls. Here, we determined the rate and risk of fractures and post-fracture mortality in patients with alcohol-related cirrhosis compared to individuals from the general population.MethodsIn this nationwide population-based cohort study, data were retrieved …
Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma
National guidelines on transplant selection have adopted successful downstaging to within Milan criteria (MC) as a viable option for the treatment of hepatocellular carcinoma (HCC) before liver transplant (LT). Recurrence of HCC after LT carries a poor prognosis, and treatment modalities remain challenging.Objective To establish the 10-year outcomes of patients with HCC after LT in …
Continue reading Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
Predicting liver cancer riskNonalcoholic fatty liver disease (NAFLD) raises the risk of developing hepatocellular carcinoma (HCC), but this risk can be difficult to quantify and disease onset can still be difficult to catch early. Fujiwara et al. developed hepatic transcriptome and serum secretome–derived signatures to predict NAFLD-related HCC in patients over 15 years of observation. …
Interleukin-27 signaling serves as an immunological checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma
AbstractWhile inflammatory mechanisms driving hepatocellular carcinoma (HCC) had been proposed, the regulators of anti-cancer immunity in HCC remain poorly understood. We found that IL-27 receptor (IL-27R) signaling promotes HCC development in vivo. High IL-27EBI3 cytokine or IL-27RA expression correlated with poor prognosis for patients with HCC. Loss of IL-27R suppressed HCC in vivo in two …
2Medical.News 